235 related articles for article (PubMed ID: 22715334)
1. The Pathogenic Role of the Adaptive Immune Response to Modified LDL in Diabetes.
Virella G; Lopes-Virella MF
Front Endocrinol (Lausanne); 2012; 3():76. PubMed ID: 22715334
[TBL] [Abstract][Full Text] [Related]
2. Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosis.
Lopes-Virella MF; Virella G
J Atheroscler Thromb; 2013; 20(10):743-54. PubMed ID: 23965492
[TBL] [Abstract][Full Text] [Related]
3. High levels of AGE-LDL, and of IgG antibodies reacting with MDA-lysine epitopes expressed by oxLDL and MDA-LDL in circulating immune complexes predict macroalbuminuria in patients with type 2 diabetes.
Lopes-Virella MF; Hunt KJ; Baker NL; Virella G;
J Diabetes Complications; 2016; 30(4):693-9. PubMed ID: 26861948
[TBL] [Abstract][Full Text] [Related]
4. Oxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes.
Hunt KJ; Baker N; Cleary P; Backlund JY; Lyons T; Jenkins A; Virella G; Lopes-Virella MF;
Atherosclerosis; 2013 Dec; 231(2):315-22. PubMed ID: 24267245
[TBL] [Abstract][Full Text] [Related]
5. The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study.
Lopes-Virella MF; Hunt KJ; Baker NL; Virella G; Moritz T;
Atherosclerosis; 2012 Oct; 224(2):526-31. PubMed ID: 22963984
[TBL] [Abstract][Full Text] [Related]
6. Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes.
Lopes-Virella MF; Hunt KJ; Baker NL; Lachin J; Nathan DM; Virella G;
Diabetes; 2011 Feb; 60(2):582-9. PubMed ID: 20980456
[TBL] [Abstract][Full Text] [Related]
7. Role of simvastatin as an immunomodulator in type 2 diabetes.
Lopes-Virella MF; Mironova M; Stephan E; Durazo-Arvizu R; Virella G
Diabetes Care; 2004 Apr; 27(4):908-13. PubMed ID: 15047647
[TBL] [Abstract][Full Text] [Related]
8. Modified LDL Immune Complexes and Cardiovascular Disease.
Lopes-Virella MF; Virella G
Curr Med Chem; 2019; 26(9):1680-1692. PubMed ID: 29792135
[TBL] [Abstract][Full Text] [Related]
9. The immunogenicity of modified lipoproteins.
Lopes-Virella MF; Thorpe SR; Derrick MB; Chassereau C; Virella G
Ann N Y Acad Sci; 2005 Jun; 1043():367-78. PubMed ID: 16037258
[TBL] [Abstract][Full Text] [Related]
10. Soluble LDL-immune complexes in type 2 diabetes and vascular disease.
Turk Z; Sesto M; Skodlar J; Ferencak G; Turk N; Stavljenić-Rukavina A
Horm Metab Res; 2002 Apr; 34(4):196-201. PubMed ID: 11987029
[TBL] [Abstract][Full Text] [Related]
11. The effects of low density lipoproteins modified by incubation with chondroitin 6-sulfate on human aortic smooth muscle cells.
Tîrziu D; Jinga VV; Serban G; Simionescu M
Atherosclerosis; 1999 Nov; 147(1):155-66. PubMed ID: 10525137
[TBL] [Abstract][Full Text] [Related]
12. Anti-modified LDL antibodies, LDL-containing immune complexes, and susceptibility of LDL to in vitro oxidation in patients with type 2 diabetes.
Mironova MA; Klein RL; Virella GT; Lopes-Virella MF
Diabetes; 2000 Jun; 49(6):1033-41. PubMed ID: 10866057
[TBL] [Abstract][Full Text] [Related]
13. The role of immune and inflammatory processes in the development of macrovascular disease in diabetes.
Lopes-Virella MF; Virella G
Front Biosci; 2003 Sep; 8():s750-68. PubMed ID: 12957881
[TBL] [Abstract][Full Text] [Related]
14. Anti-modified LDL antibodies and LDL-containing immune complexes in IDDM patients and healthy controls.
Mironova M; Virella G; Virella-Lowell I; Lopes-Virella MF
Clin Immunol Immunopathol; 1997 Oct; 85(1):73-82. PubMed ID: 9325072
[TBL] [Abstract][Full Text] [Related]
15. Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes.
Lopes-Virella MF; Baker NL; Hunt KJ; Lachin J; Nathan D; Virella G;
Atherosclerosis; 2011 Feb; 214(2):462-7. PubMed ID: 21156319
[TBL] [Abstract][Full Text] [Related]
16. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus.
Lopes-Virella MF; Virella G; Orchard TJ; Koskinen S; Evans RW; Becker DJ; Forrest KY
Clin Immunol; 1999 Feb; 90(2):165-72. PubMed ID: 10080827
[TBL] [Abstract][Full Text] [Related]
17. Immunoassay of modified forms of human low density lipoprotein in isolated circulating immune complexes.
Virella G; Colglazier J; Chassereau C; Hunt KJ; Baker NL; Lopes-Virella MF
J Immunoassay Immunochem; 2013; 34(1):61-74. PubMed ID: 23323982
[TBL] [Abstract][Full Text] [Related]
18. Immune complexes containing malondialdehyde (MDA) LDL induce apoptosis in human macrophages.
Virella G; Wilson K; Elkes J; Hammad SM; Rajab HA; Li Y; Chassereau C; Huang Y; Lopes-Virella M
Clin Immunol; 2018 Feb; 187():1-9. PubMed ID: 28689783
[TBL] [Abstract][Full Text] [Related]
19. High-density lipoprotein inhibits the uptake of modified low- density lipoprotein and the expression of CD36 and FcgammaRI.
Carvalho MD; Vendrame CM; Ketelhuth DF; Yamashiro-Kanashiro EH; Goto H; Gidlund M
J Atheroscler Thromb; 2010 Aug; 17(8):844-57. PubMed ID: 20467189
[TBL] [Abstract][Full Text] [Related]
20. Development of capture assays for different modifications of human low-density lipoprotein.
Virella G; Derrick MB; Pate V; Chassereau C; Thorpe SR; Lopes-Virella MF
Clin Diagn Lab Immunol; 2005 Jan; 12(1):68-75. PubMed ID: 15642987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
